Consideration of Osteoporosis Risk in Selecting Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease Patients: Budesonide vs Fluticasone?
DOI:
https://doi.org/10.58600/eurjther2941Keywords:
budesonide, chronic obstructive pulmonary disease, fluticasone, inhaled corticosteroids, osteoporosisAbstract
Objective: The use of medium and low-dose inhaled corticosteroids (ICS) did not increase the risk of osteoporosis in individuals with chronic obstructive pulmonary disease (COPD). The goal is to look at the risk of osteoporosis that comes with Budesonide and Fluticasone when choosing ICS for people with COPD, since this group of people is more likely to get osteoporosis.
Methods: Patients with Stage E COPD who were on ICS and came to a tertiary healthcare facility between January 2024 and January 2025 were included. There were three groups in the trial: people with COPD who were taking inhaled budesonide, those who were on fluticasone, and a control group.
Results: The study comprised 122 participants: 16 COPD patients utilizing inhaled fluticasone, 16 COPD patients utilizing inhaled budesonide, and 90 individuals in the control group. The mean age of the study participants was 72.79 years; the mean age of the fluticasone group was 74.69 years, the mean age of the budesonide group was 73.19 years, and the mean age of the control group was 72.38 years. The groups exhibit no significant difference for osteoporosis (p>0.05). No significant difference was seen between the groups for the duration and intensity of ICS use (p>0.05).
Conclusion: In individuals with COPD, the administration of budesonide and fluticasone as inhaled corticosteroid options has not elevated the risk of osteoporosis.
References
[1] Consensus A. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993;94(6):646–650. https://doi.org/10.1016/0002-9343(93)90218-E
[2] Chen YW, Ramsook AH, Coxson HO, Bon J, Reid WD. Prevalence and risk factors for osteoporosis in individuals with COPD: a systematic review and meta-analysis. Chest. 2019;156(6):1092–1110. https://doi.org/10.1016/j.chest.2019.06.036
[3] Graat-Verboom L, Spruit MA, van den Borne BE, Smeenk FW, Martens EJ, Lunde R, Wouters EF.Correlates of osteoporosis in chronic obstructive pulmonary disease: An underestimated systemic component. Respir Med 2009;103:1143-51. https://doi.org/10.1016/j.rmed.2009.02.014.
[4] Inoue D, Watanabe R, Okazaki R. COPD and osteoporosis: links, risks, and treatment challenges. Int J Chron Obstruct Pulmon Dis. 2016;11:637–648. https://doi.org/10.2147/COPD.S79638
[5] Kanis JA, Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int. 1994;4(6):368–381. https://doi.org/10.1007/BF01622200
[6] Patel N. An update on COPD prevention, diagnosis, and management: The 2024 GOLD Report. Nurse Pract. 2024;49(6):29-36. https://doi.org/10.1097/01.NPR.0000000000000180
[7] Juby AG, Davis P. A prospective evaluation of the awareness, knowledge, risk factors and current treatment of osteoporosis in a cohort of elderly subjects. Osteoporos Int 2001;12:617-22. https://doi.org/10.1007/s001980170060.
[8] Lindberg A, Jonsson AC, Rönmark E, Lundgren R, Larsson LG, Lundbäck B. Ten-year cumulative incidence of COPD and risk factors for incident disease in a symptomatic cohort. Chest 2005;127:1544-52. https://doi.org/10.1378/chest.127.5.1544
[9] Kwok WC, Tsui CK, Leung SHI, Ngai SM, Lam DCL, Ip MSM, Ho JCM. Dose of Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease and Risks of Osteoporosis or Fracture-A Systematic Review and Meta-Analysis. Clin Respir J. 2025 May;19(5):e70086. https://doi.org/10.1111/crj.70086.
[10] Zhang N, Fan X, Zhang Y, Xu N, Li L. Risk of Fracture and Osteoporosis in Patients With COPD and Inhaled Corticosteroids Treatment. Respir Care. 2023 Nov 25;68(12):1719-1727. https://doi.org/10.4187/respcare.10933.
[11] Cornelius T. Clinical guideline highlights for the hospitalist: GOLD COPD update 2024. J Hosp Med. 2024;19(9):818-820. https://doi.org/10.1002/jhm.13416
[12] Compston J. Glucocorticoid‐induced osteoporosis: an update. Endocrine. 2018;61(1):7‐16. https://doi.org/10.1007/s12020-018-1588-2
[13] Amiche MA, Albaum JM, Tadrous M, Pechlivanoglou P, Lévesque LE, Adachi JD, Cadarette SM. Fracture risk in oral glucocorticoid users: a Bayesian meta‐regression leveraging control arms of osteoporosis clinical trials. Osteoporos Int. 2016;27(5):1709‐1718. https://doi.org/10.1007/s00198-015-3455-9
[14] Seckl JR. 11beta‐hydroxysteroid dehydrogenases: changing glucocorticoid action. Curr Opin Pharmacol. 2004;4(6):597‐602. https://doi.org/10.1016/j.coph.2004.09.001
[15] Lu P, Yang Y, Guo S, Yang T. Factors associated with osteoporosis in patients with chronic obstructive pulmonary disease—a nationwide retrospective study. Osteoporos Int. 2017;28(1):359‐367. https://doi.org/10.1007/s00198-016-3732-2
[16] Mazziotti G, Formenti AM, Adler RA, Bilezikian JP, Grossman A, Sbardella E, Minisola S, Giustina A. Glucocorticoid‐induced osteoporosis: pathophysiological role of GH/IGF‐I and PTH/VITAMIN D axes, treatment options and guidelines. Endocrine. 2016;54(3):603‐611. https://doi.org/10.1007/s12020-016-1146-8
[17] Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J Suppl. 2003;41:46-53. https://doi.org/10.1183/09031936.03.00078002
[18] Ferguson GT, Calverley PMA, Anderson JA, Jenkins CR, Jones PW, Willits LR, Yates JC, Vestbo J, Celli B.Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a revolution in COPD Health study. Chest. 2009;136(6):1456–1465. https://doi.org/10.1378/chest.08-3016
[19] Johnell O, Pauwels R, Löfdahl CG, Laitinen LA, Postma DS, Pride NB, Ohlsson SV. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler. Eur Respir J. 2002;19(6):1058–1063. https://doi.org/10.1183/09031936.02.00276602
[20] Maltais F, Schenkenberger I, Wielders PLML, Ortiz de Saracho J, Chinsky K, Watkins M, Millar V, Crim C. Effect of once-daily fluticasone furoate/vilanterol versus vilanterol alone on bone mineral density in patients with COPD: a randomized, controlled trial. Ther Adv Respir Dis. 2020;14:1753466620965145. https://doi.org/10.1177/1753466620965145.
[21] Huang HF, Hsu CW, Hsieh FT, Liao KM. Evaluating inhaled corticosteroids’ impact on osteoporosis and fracture risk in COPD patients: a real-world evidence-based systematic review and meta-analysis. Front Med (Lausanne).2025;12:1503475. https://doi.org/10.3389/fmed.2025.1503475
[22] Kallieri M, Hillas G, Bartziokas K, Loukides S, Toumpanakis D. COPD and the burden of multimorbidity: navigating the complexity. Expert Rev Respir Med. https://doi.org/10.1080/17476348.2025.2569126
[23] Li C, Gong H, Shi P, Liu S, Zhang Q. Different Forms of Regulated Cell Death in Type-2-Diabetes-Mellitus-Related Osteoporosis: A Focus on Mechanisms and Therapeutic Strategies. Int J Mol Sci. 2025;26(9):4417. https://doi.org/10.3390/ijms26094417
Downloads
Published
How to Cite
License
Copyright (c) 2026 Ali Erol, Feridun Gürlek , Fatih Alp , Sümeyye Yaylacı , Enes Kocaman , Orkun Terzi , Şule Kızıltaş , Mehmet Karaçalı , Neslihan Erol , Muhammed Fatih Şahin , Aydın Dursun
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
